| Literature DB >> 34482833 |
Hai-Cheng Zhao1, Qing-Song Xu2, Yi-Bing Shi2, Xi-Juan Ma3.
Abstract
BACKGROUND: There is a lack of clinical-radiological predictive models for the small (≤ 20 mm) solitary pulmonary nodules (SPNs). We aim to establish a clinical-radiological predictive model for differentiating malignant and benign small SPNs.Entities:
Keywords: Diagnosis; Pre-test probability; Predictive model; Small solitary pulmonary nodule
Mesh:
Year: 2021 PMID: 34482833 PMCID: PMC8419959 DOI: 10.1186/s12890-021-01651-y
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Baseline data of the training group
| Malignant (n = 156) | Benign (n = 94) | P value | |
|---|---|---|---|
| Gender (male/female) | 85/71 | 56/38 | 0.432 |
| Age (y) | 65.4 | 53.5 | < 0.001 |
| Smoking history | 72 | 38 | 0.377 |
| Malignant history | 5 | 1 | 0.519 |
| Diameter (mm) | 16.8 | 13.6 | < 0.001 |
| Lobulation | 114 | 49 | 0.001 |
| Spiculation | 120 | 47 | < 0.001 |
| Pleural retraction sign | 75 | 17 | < 0.001 |
| CT bronchus sign | 104 | 34 | < 0.001 |
| Calcification | 3 | 9 | 0.006 |
| Mediastinal/hilar lymph nodule ≥ 10 mm | 38 | 14 | 0.074 |
| 0.951 | |||
| Upper | 67 | 40 | |
| Non-upper | 89 | 54 | |
| 0.897 | |||
| Left | 76 | 45 | |
| Right | 80 | 49 | |
| CEA (ug/L) | 3.9 | 2.3 | < 0.001 |
| Cyfra21-1 (ng/ml) | 13.5 | 12.7 | 0.099 |
| SCC (ug/L) | 1.4 | 1.1 | 0.211 |
| NSE (ng/ml) | 2.5 | 2.4 | 0.423 |
CEA: Carcinoembryonic antigen; CT: Computed tomography; NSE: Neuron-specific enolase; SCC: Squamous cell carcinoma antigen
Pathological diagnoses in the training group
| Malignant | 156 |
| Adenocarcinoma | 112 |
| Squamous cell carcinoma | 33 |
| Adenosquamous carcinoma | 7 |
| Small-cell lung cancer | 4 |
| Benign | 94 |
| Inflammatory pseudotumor | 70 |
| Hamartoma | 11 |
| Tuberculoma | 8 |
| Lymph nodule | 4 |
| Mycotic infection | 1 |
Predictors of malignancy
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | Hazard ratio | 95% CI | |||
| Age | 1.120 | 1.085–1.157 | < 0.001 | 1.138 | 1.092–1.186 | |
| Size | 1.177 | 1.107–1.252 | < 0.001 | 1.086 | 0.995–1.181 | 0.065 |
| Lobulation | 2.493 | 1.456–4.267 | 0.001 | 2.143 | 0.980–4.689 | 0.056 |
| Spiculation | 3.333 | 1.924–5.776 | < 0.001 | 0.739 | 0.302–1.806 | 0.507 |
| Pleural retraction sign | 4.194 | 2.274–7.734 | < 0.001 | 3.366 | 1.431–7.920 | |
| CT bronchus sign | 3.529 | 2.064–6.035 | < 0.001 | 2.608 | 1.190–5.714 | |
| Calcification | 0.185 | 0.049–0.702 | 0.013 | 0.190 | 0.024–1.517 | 0.117 |
| Mediastinal/hilar lymph nodule ≥ 10 mm | 1.840 | 0.937–3.615 | 0.077 | 0.732 | 0.312–1.720 | 0.475 |
| CEA | 1.313 | 1.117–1.544 | 0.001 | 1.234 | 1.032–1.475 | |
CEA: Carcinoembryonic antigen; CI: confident interval; CT: computed tomography
Fig. 1The ROC curve generated using the predictor from training group
Baseline data between the training and validation group
| Training (n = 250) | Validation (n = 101) | P value | |
|---|---|---|---|
| Gender (male/female) | 141/109 | 49/52 | 0.180 |
| Age (y) | 60.9 | 61.4 | 0.723 |
| Smoking history | 110 | 43 | 0.807 |
| Malignant history | 6 | 2 | 1.000 |
| Diameter (mm) | 15.6 | 15.9 | 0.534 |
| Lobulation | 163 | 62 | 0.500 |
| Spiculation | 157 | 67 | 0.532 |
| Pleural retraction sign | 92 | 36 | 0.839 |
| CT bronchus sign | 138 | 58 | 0.704 |
| Calcification | 12 | 2 | 0.264 |
| Mediastinal/hilar lymph nodule ≥ 10 mm | 52 | 24 | 0.542 |
| 0.705 | |||
| Upper | 107 | 41 | |
| Non-upper | 143 | 60 | |
| 0.390 | |||
| Left | 121 | 54 | |
| Right | 129 | 47 | |
| CEA (ug/L) | 3.3 | 3.2 | 0.886 |
| Cyfra21-1 (ng/ml) | 2.5 | 2.4 | 0.604 |
| SCC (ug/L) | 1.3 | 1.4 | 0.614 |
| NSE (ng/ml) | 13.2 | 13.1 | 0.890 |
| 0.865 | |||
| Malignant | 156 | 64 | |
| Benign | 94 | 37 | |
CEA: Carcinoembryonic antigen; CT: Computed tomography; NSE: Neuron-specific enolase; SCC: Squamous cell carcinoma antigen
Fig. 2AUC comparison between our, Wang et al. and Swensen et al. models. The three ROC curves were generated using the data in validation group